Truist Securities Raises Jazz Pharmaceuticals Price Target to $205

Truist Securities raised Jazz Pharmaceuticals' (JAZZ) price target to $205, a 2.50% increase from $200. Analyst Gregory Fraser maintained the "Buy" rating. The stock is listed on the NASDAQ exchange. On average, 17 analysts predict an upside of 48.22% from the current price of $124.43, with a consensus rating of 1.7, indicating "Outperform" status.

Truist Securities has elevated its price target for Jazz Pharmaceuticals (JAZZ) to $205, representing a 2.50% increase from its previous target of $200. Analyst Gregory Fraser maintained the "Buy" rating on the stock, which is listed on the NASDAQ exchange. The new target reflects a significant upside of 48.22% from the current price of $124.43, with an average analyst consensus rating of 1.7, indicating an "Outperform" status [2].

The upward revision comes amidst a series of strategic developments at Jazz Pharmaceuticals. On August 20, 2025, the company announced an exclusive global license agreement with Jazz Pharmaceuticals, granting the latter worldwide rights to develop and commercialize SAN2355, a preclinical epilepsy drug candidate. Jazz Pharmaceuticals is responsible for all further development and commercialization, while Saniona is eligible to receive up to US$1 billion in upfront, milestone, and royalty payments [1]. This collaboration underscores Jazz Pharmaceuticals' commitment to expanding its neurology pipeline, particularly in the face of increased competition and looming patent expirations.

The latest move by Truist Securities is also influenced by Jazz Pharmaceuticals' recent regulatory approval for Modeyso™ (dordaviprone) in early August. This approval, which directly impacts short-term revenue potential, offers a meaningful new growth stream, especially as the company broadens its rare disease portfolio. The accelerated FDA approval sets the stage for potential mitigation of generic competition and margin compression pressures [1].

Despite the positive outlook, Jazz Pharmaceuticals' high debt load remains a significant risk factor. The company's debt load could impact future financial flexibility if revenue growth does not accelerate as projected. However, the recent licensing agreement and Modeyso™ approval suggest that Jazz Pharmaceuticals is well-positioned to navigate these challenges through innovation and strategic partnerships [1].

In conclusion, Truist Securities' revised price target for Jazz Pharmaceuticals reflects a bullish outlook on the company's strategic initiatives and recent regulatory approvals. Investors should closely monitor Jazz Pharmaceuticals' progress in expanding its neurology pipeline and managing its debt load to assess the potential for further upside.

References:
[1] https://finance.yahoo.com/news/saniona-partnership-ceo-change-might-101103779.html
[2] https://finance.yahoo.com/news/bofa-raises-pt-jazz-pharmaceuticals-035706393.html